GSK3B and Alzheimer disease: For example, GSK3B has been studied as a target for drug discovery in the treatment of nervous system disorders (121, 122), and a brain penetrable and orally active GSK3 inhibitor has been reported as a clinical candidate for Alzheimer’s disease and progressed into Phase 1 clinical trials (122).